<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004483</url>
  </required_header>
  <id_info>
    <org_study_id>199/14226</org_study_id>
    <secondary_id>HEI-NF2</secondary_id>
    <secondary_id>HEI-DAMD17-01-1-0710</secondary_id>
    <nct_id>NCT00004483</nct_id>
  </id_info>
  <brief_title>NF2 Natural History Consortium</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>House Ear Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Define the growth rates and clinical course of NF2-related tumors in patients with&#xD;
      neurofibromatosis type 2. Associate growth rate with physical function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Data on the clinical course and growth rate of NF2-related tumors in&#xD;
      patients with neurofibromatosis 2. Patients are evaluated each year on a cranial and a spinal&#xD;
      MRI, eye tests, hearing tests, quality of life, neurological tests, and physical functioning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2002</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Natural History</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Schwannoma, Vestibular</condition>
  <condition>Neurofibromatosis 2</condition>
  <condition>Meningioma</condition>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Diagnosed with neurofibromatosis 2 on or after 01/01/93&#xD;
&#xD;
          -  Must meet one of the following conditions:&#xD;
&#xD;
        Bilateral vestibular schwannoma OR Family history of neurofibromatosis 2 (first degree&#xD;
        family relative) AND Unilateral vestibular schwannoma at under 30 years OR Any 2 of the&#xD;
        following: Meningioma Glioma Schwannoma Juvenile posterior subcapsular lenticular&#xD;
        opacity/juvenile cortical cataract&#xD;
&#xD;
          -  No plans to treat vestibular schwannoma in next 12 months&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 5 and over&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William H. Slattery, III</last_name>
    <role>Study Chair</role>
    <affiliation>House Ear Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>House Ear Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057-9927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Masuda, Ann. Slattery, William H. III, Fisher, Laurel M., Oppenheimer, Mark. Audiological Characteristics of Initial Presentation of NF2 Patients: Preliminary Results. Abstract submitted to: Combined Otolaryngological Spring Meetings (COSM).</citation>
  </reference>
  <reference>
    <citation>Fisher, Laurel M., Slattery, WIlliam H. III, Yoon, Gloria. MRI Test-Retest Study of NF2 Patients. Abstract Submitted to: Combined Otolaryngological Spring Meetings (COSM).</citation>
  </reference>
  <reference>
    <citation>Slattery, William H. III, Fisher, Laurel M. Considerations in the Development of the NF2 Natural History Consortium. Submitted to Otolaryngology-Head and Neck Surgery.</citation>
  </reference>
  <reference>
    <citation>Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH; Natural History Consortium. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol. 2004 Mar;25(2):150-4. doi: 10.1097/00129492-200403000-00012.</citation>
    <PMID>15021775</PMID>
  </reference>
  <reference>
    <citation>Slattery WH, Lev MH, Fisher LM, Connell SS, Iqbal Z, Go JL; NF2 Natural History Consortium. MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation. Otol Neurotol. 2005 Jul;26(4):733-40. doi: 10.1097/01.mao.0000169048.15889.80.</citation>
    <PMID>16015177</PMID>
  </reference>
  <reference>
    <citation>Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol. 2004 Sep;25(5):811-7. doi: 10.1097/00129492-200409000-00027.</citation>
    <PMID>15354016</PMID>
  </reference>
  <reference>
    <citation>Zacharia, T., Lev, M., Iqbal, Z.T., Fisher ,L.M. , Gupta, MS, Slattery, WH. (2003) Intramedullary Spinal Tumors In NF II: Incidence And Imaging Characteristics American Radiology Society, 2003.</citation>
  </reference>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>September 27, 2005</last_update_submitted>
  <last_update_submitted_qc>September 27, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neurofibromatosis 2</mesh_term>
    <mesh_term>Neuroma, Acoustic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

